CB1 cannabinoid receptor induction in experimental stroke.

“Cannabinoids protect cortical neurons from ischemic injury by interacting with CB1 receptors. Because a variety of neuroprotective genes are induced in cerebral ischemia, we examined the effect of experimental stroke, produced by 20 minutes of middle cerebral artery occlusion in rats, on CB1 receptor expression.

Western blotting and immunohistochemistry showed that CB1 expression on neurons was increased in the arterial boundary zone of the cortical mantle, beginning by 2 hours and persisting for 72 hours or more after ischemia.

These findings are consistent with a neuroprotective role for endogenous cannabinoid signaling pathways and with a potential therapeutic role in stroke for drugs that activate CB1 receptors.”

http://www.ncbi.nlm.nih.gov/pubmed/10939579

Increased Severity of Stroke in CB1 Cannabinoid Receptor Knock-Out Mice

“These findings indicate that endogenous cannabinoid signaling pathways protect mice from ischemic stroke by a mechanism that involves CB1 receptors, and suggest that both blood vessels and neurons may be targets of this protective effect.

 Endogenous cannabinoid signaling pathways have been implicated in protection of the brain from hypoxia, ischemia, and trauma…

Cannabinoids, which include the marijuana constituent Δ9-tetrahydrocannabinol and endogenous cannabinoids (endocannabinoids) produced in the brain, exert many of their effects through the G-protein-coupled CB1 receptor.

Cannabinoids reduce neuronal death from a variety of insults, including excitotoxicity, oxidative stress, hypoxia, ischemic stroke and trauma…

Clinical stroke, which usually results from cerebral ischemia, is a common and frequently incapacitating problem for which satisfactory treatment is generally unavailable. Identifying new endogenous systems that mitigate ischemic brain injury through effects on neurons, blood vessels, or both (such as the endocannabinoid signaling pathway) may help to guide the search for improved therapies.”

Full text: http://www.jneurosci.org/content/22/22/9771.long

Endocannabinoids and obesity.

“A safe and effective antiobesity drug is needed to combat the global obesity epidemic. The discovery of cannabinoids from medicinal herbs has revealed the endocannabinoid system (ECS) in animals and humans, which regulates various physiological activities such as feeding, thermogenesis, and body weight (BW).

Although cannabinoid receptors 1 (CB1) antagonists have shown antiobesity efficacies in animal models and in the clinic, they failed to establish as a treatment due to their psychological side effects.

 Recent studies indicate that CB1 in various peripheral tissues may mediate some of the therapeutic effects of CB1 antagonists, such as improved lipid and glucose homeostasis.

 It rationalizes the development of compounds with limited brain penetration, for minimizing the side effects while retaining the therapeutic efficacies. A survey of the literature has revealed some controversies about how the ECS affects obesity. This review summarizes the research progresses and discusses some future perspectives.”

http://www.ncbi.nlm.nih.gov/pubmed/23374723

Marijuana Oil Cured My Skin Cancer

“When his cancer came back for a fifth time, Michael McShane was desperate for treatment outside of traditional medicine.

The last time squamous cell carcinoma left lumpy tumors around his mouth, doctors cut it away and reconstructed his bottom lip by turning out a portion of its inner layer.

“You can only do most facial tricks once,” McShane, 51, said. “I needed another option.”

As a qualifying medical marijuana patient, he tried “Simpson oil” derived from cannabis plants by a Canadian named Rick Simpson. McShane bought some from an Oak Park dispensary that has since closed and puts a few drops every day on his face. Over the course of about 10 weeks, the tumors faded and then seemed to disappear.

His dermatologist, Ali Moiin, M.D., has said McShane isn’t cured but his cancer cells have decreased by about 60 percent.

“You still have some residual ones, but the size has definitely decreased,” Dr. Moiin told a WWJ reporter in late August, adding he thinks the results merit further scientific study.

Moiin didn’t return phone calls for an interview for this story. He isn’t the doctor who signed the physician certification form for McShane, who has another qualifying medical problem.

In all, since the Michigan Medical Marijuana Program started in April 2009, 2,215 of the state’s licensed physicians have certified that a patient suffers from one of the debilitating conditions identified in the act, and that the patient may find therapeutic and palliative relief from the medical use of marijuana. A total of 105,458 patient registry cards have been issued in that time period.

An estimated 55 doctors signed 70 percent of the certification forms, according to one review; most of the others aren’t talking about it publicly.

“I imagine it is a fairly sensitive issue because it is politically charged,” said Colin Ford, director of state and federal government relations for the Michigan State Medical Society.

Physicians are cautious because patient privacy is important, he said.

A forbidden cure?

Privacy isn’t as important to McShane as sharing what he considers his latest triumph over cancer without surgery, radiation, chemotherapy, reconstructive surgery and their side effects.

“The marijuana oil replaced all that and reduced the cancer to almost nothing,” he said. “My forehead and mouth were in bad shape in the spring. All of a sudden one morning it was there — a callous-like growth the size of a half dollar on my forehead. Skin cancer is my regular nemesis.”

McShane is one of a growing number of people extolling the healing properties of Simpson oil for everything from cancer, AIDS, Crohn’s disease, osteoporosis, arthritis, and diabetes to psoriasis, hemorrhoids and warts. They call it a “forbidden cure,” saying the oil that can be used topically or ingested isn’t given enough credit because it would cut into medical and pharmaceutical profits.”

By Catherine Kavanaugh
Daily Tribune Staff Writer

Video: http://www.youtube.com/watch?v=gr8RPjrsYSI

Cannabis Oil Cures Skin Cancer

“After yesterday’s post about how cannabis oil helped a two-year old recover from a brain tumor, we thought we’d share another medical marijuana success story involving canna-oil. Cannabis Science, Inc., a pioneering U.S. biotech company developing pharmaceutical cannabis products, demonstrated yet another occurrence of medical marijuana’s important role in curing cancer. The firm issued a press release that shows cannabis extracts appeared to be effective against a patient’s third incidence of basal cell carcinoma—the most common form of cancer with over 800,000 cases occurring annually in the US. 

The patient was an Australian woman from Queensland, the site of the highest rate of skin cancer in the world. She had numerous surgeries to remove previous lesions on her face including a basal cell carcinoma, but her lesions kept coming back. She then used cannabis oil topically as an alternative therapy – and it worked! Cannabis Science released a PDF that includes a series of photos that documents the disappearance of the lesion after ten days of self-administering topical cannabis extracts. They then received verbal confirmation from her physician that the sites of the former cancerous lesions are free of cancer cells. 

This is an amazing recovery from this patient, however the results aren’t atypical. Over 600 peer reviewed articles show that numerous cancer types (including lung, breast, prostate, glioma, thyroid, leukemia, lymphoma, basil cell carcinoma and melanoma) are killed by cannabinoids in tissue culture and animal studies. We know that medical marijuana  is effective against many diseases and ailments, including cancer—which is precisely why 15 states and Washington DC have passed medical marijuana laws allowing for the medical use of cannabis. It’s time that the rest of the country catches up. Let’s give patients the effective and safe medicine they need and deserve.”

https://www.marijuanadoctors.com/blog/marijuana-medical-conditions/Cannabis-Oil-Cures-Skin-Cancer

Skin Cancer Patient Says Oil From Medical Marijuana Is A Cure

“A Ferndale man claims he’s found a cure for his cancer and it’s now legal in Michigan.”

%name Skin Cancer Patient Says Oil From Medical Marijuana Is A Cure.

“WWJ’s Sandra McNeill spoke with Michael McShane who claims he’s been using a topical oil made from medical marijuana on the skin cancer on his forehead and in just over two months it’s nearly gone.

“I’ve got biopsies, chart notes, photographs … in about three weeks I’m going to go back  and really wrap this part of the case up,” said McShane. “It’s made the same way a lot of the fragrances and perfumes are made, and the oil is applied, in my case, directly to the skin, and within 10 weeks my cancer is gone.

“From a topical standpoint I don’t experience any euphoria,” said McShane.

McShane freely admits that he has smoked marijuana since he was in his teens, “It went from a party to a cure for cancer,” he said.”

Read more: http://detroit.cbslocal.com/2011/08/29/skin-cancer-patient-says-oil-from-medical-marijuana-is-a-cure/

Cannabinoid receptors as novel targets for the treatment of melanoma

“Melanoma causes the greatest number of skin cancer-related deaths worldwide. Here, we evaluated the efficacy of cannabinoid receptor agonists, a new family of potential antitumoral compounds, at skin melanoma. Human melanomas and melanoma cell lines express CB1 and CB2 cannabinoid receptors. Activation of these receptors decreased growth, proliferation, angiogenesis and metastasis, and increased apoptosis, of melanomas in mice. Cannabinoid antimelanoma activity was independent of the immune status of the animal, could be achieved without overt psychoactive effects and was selective for melanoma cells vs. normal melanocytes.

Cannabinoid antiproliferative action on melanoma cells…

 These findings may contribute to the design of new chemotherapeutic strategies for the management of melanoma.

 …the present report, together with the implication of CB2 receptors in the control of processes such as pain initiation, emesis, and inflammation, opens the attractive possibility of finding cannabinoid-based therapeutic strategies devoid of nondesired psychotropic side effects.

Specifically, the antiproliferative effect of cannabinoids reported here may set the basis for a new therapeutic approach for the treatment of malignant melanoma.”

Full text: http://www.fasebj.org/content/20/14/2633.long

Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors

“Cannabinoids inhibit skin tumor growth in vivo. Here we show that the CB1 and the CB2 receptor are expressed in normal skin and skin tumors of mice and humans. In cell culture experiments pharmacological activation of cannabinoid receptors induced the apoptotic death of tumorigenic epidermal cells, whereas the viability of nontransformed epidermal cells remained unaffected. Local administration of the mixed CB1/CB2 agonist WIN-55,212-2 or the selective CB2 agonist JWH-133 induced a considerable growth inhibition of malignant tumors generated by inoculation of epidermal tumor cells into nude mice. Cannabinoid-treated tumors showed an increased number of apoptotic cells.

 

Cannabinoids, the active components of Cannabis sativa linnaeus (marijuana)…

Marijuana and its derivatives have been used in medicine for many centuries, and currently there is a renaissance in the study of the therapeutic effects of cannabinoids… cannabinoids may be potential antitumoral agents owing to their ability to induce the regression of various types of tumors, including lung adenocarcinoma, glioma, and thyroid epithelioma in animal models.

This background prompted us to explore whether (a) the skin and skin tumors express cannabinoid receptors; (b) cannabinoid receptor activation exerts a growth-inhibiting action on skin tumors in vivo; and (c) inhibition of angiogenesis is implicated in the anti-tumoral effect of cannabinoids.

Our data show that (a) CB1 and CB2 receptors are present in the skin and skin tumors; (b) local cannabinoid receptor activation induces the regression of skin tumors in vivo; and (c) at least two mechanisms may be involved in this action: direct apoptosis of tumor cells and inhibition of tumor angiogenesis.

These results support a new therapeutic approach for the treatment of skin tumors.”

Full text: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC151833/

Revisiting CB1 receptor as drug target in human melanoma.

“Previous studies have indicated the antitumoral effect of human melanocytes, human melanoma cell lines expressing CB1 receptor (CB1), and of the peritumoral administration of endocannabinoids. In the present study, we systematically screened several human melanoma cell lines for the expression of CNR1 and demonstrated transcription of the authentic gene. The product of CNR1, the CB1 protein, was found localized to the cell membrane as well as to the cytoskeleton. Further, the studied human melanoma cell lines expressed functional CB1 since physiological and synthetic ligands, anandamide (AEA), Met-F-AEA, ACEA and AM251 showed a wide range of biological effects in vitro, for example anti-proliferative, proapoptotic and anti-migratory. More importantly, our studies revealed that systemic administration of a stable CB1 agonist, ACEA, into SCID mice specifically inhibited liver colonization of human melanoma cells.

Since therapeutic options for melanoma patients are still very limited, the endocannabinoid-CB1 receptor system may offer a novel target.”

http://www.ncbi.nlm.nih.gov/pubmed/22447182

The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities

“The endocannabinoid system (ECS) and the skin. Recent studies have intriguingly suggested the existence of a functional ECS in the skin and implicated it in various biological processes. It seems that the main physiological function of the cutaneous ECS is to constitutively control the proper and well-balanced proliferation, differentiation and survival, as well as immune competence and/or tolerance, of skin cells. The disruption of this delicate balance might facilitate the development of multiple pathological conditions and diseases of the skin (e.g. acne, seborrhea, allergic dermatitis, itch and pain, psoriasis, hair growth disorders, systemic sclerosis and cancer).

Perspectives in the ECS-targeted management of skin diseases

… preclinical data encourage one to systematically explore whether ECS-modulating drugs can be exploited in the management of common skin disorders…

 … we review preliminary data and discuss the possible applications of ECS-targeted therapies…ECS-targeted approaches in skin diseases. Modulations of the fine-tuned tone of the cutaneous endocannabinoid system (ECS) could have therapeutic values in the management of a large variety of human skin diseases…

Conclusions and future directions in experimental and clinical research

… it is envisaged (this is also strongly supported by pilot studies) that the targeted manipulation of the ECS might be beneficial in a multitude of human skin diseases. However, to predict the real therapeutic potential and translate the exciting preclinical observations discussed earlier into clinical practice, numerous important questions should carefully be addressed. Nevertheless, targeting the cutaneous ECS for therapeutic gain remains an intriguing and provocative possibility warranting future studies.”

Full text: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2757311/